Margin operasi Ionis (IONS)

Simbol resmi perusahaan Ionis Pharmaceuticals (IONS)

Ionis Pharmaceuticals (IONS) generates revenue based on royalties and licenses from the development of drugs targeting genetic pathologies. Operating profit margins reflect the model's reaction to external challenges, where -58.90 indicates the current level. Business stability relies on external partner plants, while an active R&D pipeline of RNA therapies provides record growth potential.

IONS - Margin operasi Ionis Pharmaceuticals, Inc. ing rentang 04.07.2022 - 19.11.2026

IONS (Ionis Pharmaceuticals): rincian analitis lan laporan miturut indikator

- rega saham lan konsensus proyeksi valuasi:
Analisis komprehensif perusahaan:Ionis Pharmaceuticals, Inc., IONS
Produk dadi Isis Pharmaceuticals

Operating margin is calculated as the ratio of operating profit to total revenue, measuring cost management efficiency before accounting for financial and tax obligations. This metric reflects the ability of Ionis Pharmaceuticals (IONS) to convert RNA therapy sales into actual income during the portfolio scaling phase, allowing for an assessment of the business model's sustainability through the recorded operating margin.

Pesaing utama

Margin dodolan operasi TEM|QGEN - Tingkat bathi adhedhasar bathi operasi|Rentabilitas operasi Repligen Corp (RGEN)|RNA - Rentabilitas dodolan operasi|crisprtx.com - Margin dodolan operasi|Tingkat bathi operasi WGS|RARE - Rentabilitas operasi|Beam Tx (BEAM) - Margin dodolan operasi|SRPT (Sarepta Therapeutics Inc) - Margin dodolan operasi|TWST: Rasio bathi operasi|TXG (10xgenomics.com) - Margin operasi|NTLA (Intellia Therapeutics, Inc.) - Rasio bathi operasi|Rentabilitas operasi Stoke Corp (STOK)|Rentabilitas kegiatan operasi BioLife|Margin operasi WVE (Wave Life Sciences Ltd)|MAZE: Rentabilitas dodolan miturut bathi operasi|Sionna Therapeutics, Inc. - Margin operasi|Tingkat bathi operasi PRME (Prime Medicine Inc)|TSHA (Taysha Gene Therapies, Inc.) - Margin dodolan operasi|QURE - Rentabilitas kegiatan operasi|MGTX (MeiraGTx Corp) - Margin operasi|Rentabilitas dodolan operasi REGENXBIO Inc. RGNX|Rentabilitas operasi Solid Biosciences (SLDB)|Ocugen Corp - Rentabilitas dodolan miturut bathi operasi|Rentabilitas operasi Pacific Biosciences PACB|Rasio bathi operasi BNTC (Benitec)|Design Corp - Margin operasi|Rocket Pharmaceuticals - Rasio bathi operasi|Rentabilitas dodolan miturut bathi operasi 4D Molecular Therapeutics, Inc.|Rentabilitas dodolan operasi Lexeo Therapeutics (LXEO)|KRRO (Korro Bio, Inc.) - Margin operasi|Rentabilitas dodolan operasi Editas EDIT|Margin operasi SLN|ProQR Therapeutics - Rentabilitas dodolan miturut bathi operasi|Margin operasi CDXS (Codexis, Inc.)|SGMO: Rentabilitas dodolan miturut bathi operasi|Nautilus Biotechnology - Margin operasi|Tingkat bathi operasi MGX (Metagenomi, Inc)|DTIL: Margin operasi|GBIO: Rasio bathi operasi|Rentabilitas operasi Boundless Bio Inc.|Margin dodolan operasi Exicure (XCUR)|Margin operasi IMNN|PHIO (Phio Pharmaceuticals Corp.) - Tingkat bathi operasi|Mustang Bio, Inc. - Margin dodolan operasi|RNAZ - Margin dodolan operasi|BNGO: Margin dodolan operasi|APDN (Applied DNA Sciences Inc) - Rentabilitas dodolan miturut bathi operasi|BLUE (Bluebird Bio) - Margin dodolan operasi|ImmunoPrecise Antibodies Ltd - Tingkat bathi operasi|OMGA (Omega Therapeutics Inc) - Margin operasi|Rentabilitas operasi OMIC|Rentabilitas operasi Regulus Therapeutics Inc. (RGLS)|Margin dodolan operasi Syros Pharmaceuticals, Inc. SYRS|Telesis Bio - Margin dodolan operasi|Tingkat bathi operasi TCON|UBX - Rentabilitas operasi